Tomorrow Is Not Likely To Be Same For Editas Medicine Inc (EDIT)

Editas Medicine Inc (EDIT) concluded trading on Wednesday at a closing price of $2.56, with 9.52 million shares of worth about $24.36 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 111.57% during that period and on July 02, 2025 the price saw a gain of about 13.78%. Currently the company’s common shares owned by public are about 83.71M shares, out of which, 82.95M shares are available for trading.

Stock saw a price change of 16.89% in past 5 days and over the past one month there was a price change of 44.63%. Year-to-date (YTD), EDIT shares are showing a performance of -45.18% which increased to 101.57% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.91 but also hit the highest price of $6.05 during that period. The average intraday trading volume for Editas Medicine Inc shares is 2.20 million. The stock is currently trading 20.30% above its 20-day simple moving average (SMA20), while that difference is up 42.71% for SMA50 and it goes to 27.45% higher than SMA200.

Editas Medicine Inc (NASDAQ: EDIT) currently have 83.71M outstanding shares and institutions hold larger chunk of about 54.28% of that.

The stock has a current market capitalization of $214.30M and its 3Y-monthly beta is at 2.18. It has posted earnings per share of -$3.04 in the same period. It has Quick Ratio of 3.08 while making debt-to-equity ratio of 0.50. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EDIT, volatility over the week remained 12.54% while standing at 11.96% over the month.

Stock’s fiscal year EPS is expected to rise by 34.40% while it is estimated to increase by 42.87% in next year. EPS is likely to grow at an annualized rate of 27.74% for next 5-years, compared to annual growth of -1.48% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on April 28, 2025 offering a Buy rating for the stock and assigned a target price of $3 to it. On December 13, 2024, Truist Downgrade their recommendations, while on December 13, 2024, Stifel Downgrade their ratings for the stock with a price target of $3. Stock get a Neutral rating from Chardan Capital Markets on December 13, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.